Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MALIBU Trial: Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas
NCT03697512Phase 2Active, not recruiting
- Sponsor
- International Extranodal Lymphoma Study Group
- Start
- Sep 2019
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of ibrutinib in marginal zone lymphoma (MZL), sponsored by International Extranodal Lymphoma Study Group. Primary endpoints: Complete Response Rate at 12 months and Progression Free Survival at 5 years. Started Sep 2019; status: active, not recruiting.
02
Drugs
ibrutinib
03
Conditions
marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT03697512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03697512.